FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W203570421> ?p ?o ?g. }

• W203570421 endingPage "92" @default.
• W203570421 startingPage "3087" @default.
• W203570421 abstract "Cisplatin/gemcitabine are one of the standard chemotherapy schedules in locally advanced and metastatic NSCLC cancer. A number of trials documented that omission of gemcitabine on day 15 and reduction of cisplatin up to 70 mg/mq are equivalent in term of response rates to classic administrations on days 1, 8 and 15 with cisplatin 100 mg/mq. The aim of this study was to confirm this evidence and to demonstrate that a further reduction of gemcitabine dose-intensity may be performed with the same efficacy on response.Fifty untreated patients with locally advanced and metastatic NSCLC entered the study: 24 stage IIIB and 26 stage IV. The median age was 65 years (range 32-76); 44 males and 6 females Genicitabine was administered 1000 mg/mq weekly on days 1 and 8 followed by a 2-week rest and cisplatin 80 mg/mq on day 2 of each 28-day-cycle.Forty-five patients were evaluable for response and all for toxicity. The overall response rates were 35.5% with 16 partial responses (95% Confidence Interval: 32%-61%). Most of the objective responses were seen in IIIB patients (56% of the stage IIIB and 44% of the stage IV patients responded). According to the intent-to-treat-principle, the response rates were 32% (16 out of 50 patients). The median dose-intensity of gemcitabine and cisplatin was respectively 477.6 mg/mq/week (481.4 for responders) and 19.5 mg/mq/week (19.9 mg/mq for responders). The median response duration was 5 months (range 1-18) and the median time to progression was 5 months (1-21); median survival was 9 months (range 2-31). The main toxicity was haematological: thrombocytopenia grade IV in 5 patients (10%) and grade III in 11 patients (22%); neutropenia grade III-IV in 4 patients (8%); grade III anemia in 3 (6%). Asthenia was the most significant non-haematological toxicity and was observed in 19 patients (38%).This trial confirmed the efficacy of a schedule with 2 administrations of gemcitabine (on days 1, 8) and a cisplatin dose on day 2 lower than 100 mg/mq. Moreover, the same efficacy was obtained with a median-dose intensity of cisplatin and gemcitabine lower than planned in a 21-day-schedule. For safety and low toxicity, we think that this schedule provides another chance to treat patients with non-small cell lung cancer, especially the elderly or patients with coexistent medical illnesses." @default.
• W203570421 created "2016-06-24" @default.
• W203570421 creator A5002072283 @default.
• W203570421 creator A5003882744 @default.
• W203570421 creator A5018141422 @default.
• W203570421 creator A5052283742 @default.
• W203570421 creator A5055642888 @default.
• W203570421 creator A5065043145 @default.
• W203570421 creator A5066253533 @default.
• W203570421 creator A5073829389 @default.
• W203570421 creator A5076440380 @default.
• W203570421 creator A5088503165 @default.
• W203570421 date "2003-01-18" @default.
• W203570421 modified "2023-09-27" @default.
• W203570421 title "A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study." @default.
• W203570421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12530048" @default.
• W203570421 hasPublicationYear "2003" @default.
• W203570421 type Work @default.
• W203570421 sameAs 203570421 @default.
• W203570421 citedByCount "4" @default.
• W203570421 countsByYear W2035704212014 @default.
• W203570421 crossrefType "journal-article" @default.
• W203570421 hasAuthorship W203570421A5002072283 @default.
• W203570421 hasAuthorship W203570421A5003882744 @default.
• W203570421 hasAuthorship W203570421A5018141422 @default.
• W203570421 hasAuthorship W203570421A5052283742 @default.
• W203570421 hasAuthorship W203570421A5055642888 @default.
• W203570421 hasAuthorship W203570421A5065043145 @default.
• W203570421 hasAuthorship W203570421A5066253533 @default.
• W203570421 hasAuthorship W203570421A5073829389 @default.
• W203570421 hasAuthorship W203570421A5076440380 @default.
• W203570421 hasAuthorship W203570421A5088503165 @default.
• W203570421 hasConcept C126322002 @default.
• W203570421 hasConcept C143998085 @default.
• W203570421 hasConcept C2776256026 @default.
• W203570421 hasConcept C2776694085 @default.
• W203570421 hasConcept C2778239845 @default.
• W203570421 hasConcept C2780258809 @default.
• W203570421 hasConcept C29730261 @default.
• W203570421 hasConcept C31760486 @default.
• W203570421 hasConcept C71924100 @default.
• W203570421 hasConcept C90924648 @default.
• W203570421 hasConceptScore W203570421C126322002 @default.
• W203570421 hasConceptScore W203570421C143998085 @default.
• W203570421 hasConceptScore W203570421C2776256026 @default.
• W203570421 hasConceptScore W203570421C2776694085 @default.
• W203570421 hasConceptScore W203570421C2778239845 @default.
• W203570421 hasConceptScore W203570421C2780258809 @default.
• W203570421 hasConceptScore W203570421C29730261 @default.
• W203570421 hasConceptScore W203570421C31760486 @default.
• W203570421 hasConceptScore W203570421C71924100 @default.
• W203570421 hasConceptScore W203570421C90924648 @default.
• W203570421 hasIssue "5" @default.
• W203570421 hasLocation W2035704211 @default.
• W203570421 hasOpenAccess W203570421 @default.
• W203570421 hasPrimaryLocation W2035704211 @default.
• W203570421 hasRelatedWork W2349270370 @default.
• W203570421 hasRelatedWork W2354229318 @default.
• W203570421 hasRelatedWork W2361287035 @default.
• W203570421 hasRelatedWork W2366445021 @default.
• W203570421 hasRelatedWork W2381460883 @default.
• W203570421 hasRelatedWork W2416376379 @default.
• W203570421 hasRelatedWork W2804797443 @default.
• W203570421 hasRelatedWork W3026352209 @default.
• W203570421 hasRelatedWork W3155373832 @default.
• W203570421 hasRelatedWork W2093038496 @default.
• W203570421 hasVolume "22" @default.
• W203570421 isParatext "false" @default.
• W203570421 isRetracted "false" @default.
• W203570421 magId "203570421" @default.
• W203570421 workType "article" @default.